立体定向体部放疗治疗I期非小细胞肺癌后的局部控制
该研究纳入46项符合标准的研究,评估立体定向体部放疗治疗医学上无法手术的I期非小细胞肺癌的局部控制率与剂量的关系。再生长模型拟合最佳,T1、T2及T1+T2合并的α/β比分别约为25 Gy、19 Gy和21 Gy;预测达到最大局部控制率的物理剂量为3次43±1 Gy、4次47±1 Gy、5次50±1 Gy(T1+T2合并)。
要点
- 再生长模型对临床数据拟合最佳,T1、T2及合并肿瘤的α/β比分别约为25 Gy、19 Gy和21 Gy。
- 预测达到最大局部控制率的物理剂量为3次43±1 Gy、4次47±1 Gy、5次50±1 Gy(T1+T2合并)。
- 早期非小细胞肺癌对立体定向体部放疗敏感,3~5次给予43~50 Gy物理剂量时存在陡峭的剂量-反应关系。
核心结论
- 早期非小细胞肺癌对立体定向体部放疗或立体定向消融放疗具有放射敏感性,物理剂量43~50 Gy分3~5次给予时存在陡峭的剂量-反应关系并可获得高的持久局部控制率。
研究设计与样本
- 共识别160篇报告I期非小细胞肺癌立体定向体部放疗后局部控制率的已发表文章,其中46项研究符合纳入标准。
- 通过评估研究患者数、剂量方案同质性、随访时间长度及局部控制报告情况来评价系列质量。
- 将T1、T2及T1+T2合并的1、2、3、5年肿瘤控制概率作为生物有效剂量的函数,拟合线性二次模型、通用生存曲线模型和再生长模型。
主要发现
- 以拟合优度χ²/ndf衡量,三种模型均非理想拟合,其中再生长模型对临床数据的拟合最佳。
- 再生长模型拟合得出α/β比约为:T1肿瘤25 Gy,T2肿瘤19 Gy,T1+T2合并21 Gy。
- 为达到最大局部控制率,预测的物理剂量方案(处方于计划靶区周边)为:T1+T2合并肿瘤3次43±1 Gy、4次47±1 Gy、5次50±1 Gy。
局限性
- 以拟合优度χ²/ndf衡量,三种模型均非理想拟合。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Numerous dose and fractionation schedules have been used to treat medically inoperable stage I non-small cell lung cancer (NSCLC) with stereotactic body radiation therapy (SBRT) or stereotactic ablative radiation therapy. We evaluated published experiences with SBRT to determine local control (LC) rates as a function of SBRT dose. METHODS AND MATERIALS: One hundred sixty published articles reporting LC rates after SBRT for stage I NSCLC were identified. Quality of the series was assessed by evaluating the number of patients in the study, homogeneity of the dose regimen, length of follow-up time, and reporting of LC. Clinical data including 1, 2, 3, and 5-year tumor control probabilities for stages T1, T2, and combined T1 and T2 as a function of the biological effective dose were fitted to the linear quadratic, universal survival curve, and regrowth models. RESULTS: Forty-six studies met inclusion criteria. As measured by the goodness of fit χ2/ndf, with ndf as the number of degrees of freedom, none of the models were ideal fits for the data. Of the 3 models, the regrowth model provides the best fit to the clinical data. For the regrowth model, the fitting yielded an α-to-β ratio of approximately 25 Gy for T1 tumors, 19 Gy for T2 tumors, and 21 Gy for T1 and T2 combined. To achieve the maximal LC rate, the predicted physical dose schemes when prescribed at the periphery of the planning target volume are 43 ± 1 Gy in 3 fractions, 47 ± 1 Gy in 4 fractions, and 50 ± 1 Gy in 5 fractions for combined T1 and T2 tumors. CONCLUSIONS: Early-stage NSCLC is radioresponsive when treated with SBRT or stereotactic ablative radiation therapy. A steep dose-response relationship exists with high rates of durable LC when physical doses of 43-50 Gy are delivered in 3 to 5 fractions.
引用
- Lee P, Loo BW, Biswas T, et al. Local Control After Stereotactic Body Radiation Therapy for Stage I Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2019. PMID: 30954520. doi:10.1016/j.ijrobp.2019.03.045
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。